<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00397111</url>
  </required_header>
  <id_info>
    <org_study_id>070021</org_study_id>
    <secondary_id>07-M-0021</secondary_id>
    <nct_id>NCT00397111</nct_id>
  </id_info>
  <brief_title>Development of Magnetic Resonance Imaging Techniques for Studying Mood and Anxiety Disorders</brief_title>
  <official_title>Development of Functional and Structural Magnetic Resonance Imaging Techniques for the Study of Mood and Anxiety Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is intended to help develop new MRI imaging techniques for studying mood and&#xD;
      anxiety disorders. Researchers believe that depression and anxiety disorders may cause&#xD;
      structural and functional changes in the brain. This study will optimize the way MRI scans&#xD;
      are collected to look at brain structure and examine how the brain behaves while subjects&#xD;
      perform particular tasks.&#xD;
&#xD;
      Healthy normal subjects between 18 and 50 years of age who have never had a major psychiatric&#xD;
      disorder and who have no first-degree relatives with mood disorders may be eligible for this&#xD;
      study. Candidates are screened by phone with questions about their psychiatric and medical&#xD;
      history, current emotional state and sleep pattern, and family history of psychiatric&#xD;
      disorders. Candidates who pass the preliminary screening then undergo additional screening&#xD;
      interviews and laboratory tests.&#xD;
&#xD;
      Participants undergo magnetic resonance imaging (MRI) and neuropsychological testing, as&#xD;
      follows:&#xD;
&#xD;
      &quot;&lt;TAB&gt;MRI scans: Subjects are asked to participate in an MRI study on one of several scanners&#xD;
      to measure blood flow in the brain, concentrations of certain chemicals in the brain, or&#xD;
      magnetic properties of the brain. MRI uses a strong magnet and radio waves to obtain pictures&#xD;
      of the brain. The subject lies still on a narrow bed with a metal coil close to the head. For&#xD;
      this study, subjects may be asked to wear a special coil on the neck to help measure blood&#xD;
      flow. They may be asked to watch a screen presenting images or to do a task in which they&#xD;
      respond to pictures or sounds and may be asked to return for additional scans.&#xD;
&#xD;
      &quot;&lt;TAB&gt;Neuropsychological testing: Subjects may undergo tests of cognitive performance. Often,&#xD;
      people with mood disorders have subtle changes in performance on these tests that allow&#xD;
      researchers to pinpoint where brain abnormalities occur. Before the tests can be used in&#xD;
      patients, they must be validated by using healthy subjects. These tests are presented either&#xD;
      orally, in written form, or on a computer.&#xD;
&#xD;
      ...&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective&#xD;
&#xD;
      A major component of understanding the pathogenesis of mood and anxiety disorders is expected&#xD;
      to involve elucidation of abnormalities in brain structure and function associated with these&#xD;
      conditions. Historically post-mortem histopathological and neurochemical assessments&#xD;
      constituted the primary methods for investigating abnormalities of brain structure and&#xD;
      function in psychiatric disorders. However, the significance of the results from such studies&#xD;
      has been limited by the relatively poor availability of specimens from subjects with mood and&#xD;
      anxiety disorders who had been unmedicated and clinically well-characterized antemortem. By&#xD;
      allowing for in vivo human studies, medical imaging technologies provide efficient, accurate,&#xD;
      and non-invasive alternatives for characterizing brain structure and function. The recent&#xD;
      rapid development of magnetic resonance imaging (MRI) technology, in particular, has provided&#xD;
      powerful tools for assessing a wide range of cerebral physiological and morphological&#xD;
      characteristics. To optimally exploit the potential of these rapidly evolving MRI scanning&#xD;
      and hardware capabilities in investigations of mood and anxiety disorders, new techniques and&#xD;
      applications must be developed and tested. The technical development protocol proposed herein&#xD;
      will assess new imaging techniques and hardware, and will develop novel cognitive tasks for&#xD;
      application in the study of mood and anxiety disorders. The primary objective of this&#xD;
      protocol is the development of MRI experiments for characterizing the physiological&#xD;
      correlates of mood and anxiety disorders. In addition, the pilot projects encompassed within&#xD;
      this protocol involve the optimization of existing MRI pulse sequences, the application of&#xD;
      new pulse sequences for structural and functional MR imaging, and the development of new&#xD;
      functional MRI (fMRI) tasks that can elucidate neural function within the&#xD;
      cognitive-behavioral domains affected in mood and anxiety disorders. This protocol will also&#xD;
      allow testing of existing imaging hardware that can increase the spatial resolution,&#xD;
      contrast, and sensitivity of MR images. Such hardware includes the use of multi-channel radio&#xD;
      frequency (RF) coils and patient monitoring equipment. Development of these techniques and&#xD;
      applications will directly enhance the sensitivity and specificity of MRI studies of mood and&#xD;
      anxiety disorders.&#xD;
&#xD;
      Study Population&#xD;
&#xD;
      This study will involve 250 healthy volunteers and 90 patients with major depressive&#xD;
      disorder.&#xD;
&#xD;
      Design&#xD;
&#xD;
      This technical development protocol will assess new imaging techniques and hardware, and will&#xD;
      develop novel cognitive tasks for application in the study of mood and anxiety disorders.&#xD;
      Subjects may have the option to participate in one or several procedures conducted under this&#xD;
      protocol, including fMRI, Magnetic Resonance Spectroscopy (MRS), Magnetoencephalography&#xD;
      (MEG), behavioral tasks, and rating scales.&#xD;
&#xD;
      Outcome Measures&#xD;
&#xD;
      Primary outcome measures on neuropsychological tests will include parameters such as accuracy&#xD;
      and reaction time. Secondary outcome measures will include differences in reaction time or&#xD;
      accuracy between different testing conditions. Outcome measures from MRI scanning sessions&#xD;
      will include signal-to-noise ratio, contrast-to-noise ratio, structural volumes, metabolite&#xD;
      concentrations (in the case of MRS), relaxation times (in the case of relaxometry), and BOLD&#xD;
      time series (in the case of fMRI).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 6, 2006</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>BOLD time series</measure>
    <time_frame>Varies based on experiment</time_frame>
    <description>Magnetic Resonance Imaging data</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Structural volumes</measure>
    <time_frame>Varies based on experiment</time_frame>
    <description>Magnetic Resonance Imaging data</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Accuracy</measure>
    <time_frame>Varies based on experiment</time_frame>
    <description>Neuropsychological testing data</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Contrast-to-noise ratio</measure>
    <time_frame>Varies based on experiment</time_frame>
    <description>Magnetic Resonance Imaging data</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Signal-to-noise ratio</measure>
    <time_frame>Varies based on experiment</time_frame>
    <description>Magnetic Resonance Imaging data</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relaxation times</measure>
    <time_frame>Varies based on experiment</time_frame>
    <description>Reflexometry data</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolite concentrations</measure>
    <time_frame>Varies based on experiment</time_frame>
    <description>Magnetoencephalography data</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reaction time</measure>
    <time_frame>Varies based on experiment</time_frame>
    <description>Neuropsychological testing data</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reaction time between testing conditions</measure>
    <time_frame>Varies based on experiment</time_frame>
    <description>Neuropsychological testing data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accuracy between testing conditions</measure>
    <time_frame>Varies based on experiment</time_frame>
    <description>Neuropsychological testing data</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">340</enrollment>
  <condition>Mood Disorders</condition>
  <condition>Anxiety Disorders</condition>
  <arm_group>
    <arm_group_label>Healthy Volunteer</arm_group_label>
    <description>Healthy Volunteer/control group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Major Depressive Disorder</arm_group_label>
    <description>Individuals with Major Depressive Disorder</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adult healthy volunteers and individuals with major depressive disorder will be recruited&#xD;
        from the general population.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        Healthy Control:&#xD;
&#xD;
          -  Male and female subjects between 18 and 65 years of age&#xD;
&#xD;
          -  Subjects must be able to give written informed consent prior to participation in this&#xD;
             study.&#xD;
&#xD;
          -  Subjects who do not currently meet and have never met criteria for any major&#xD;
             psychiatric disorder, and who have no known first degree relatives with mood&#xD;
             disorders.&#xD;
&#xD;
          -  For cognitive experiments utilizing language stimuli only native English speakers will&#xD;
             be enrolled.&#xD;
&#xD;
        Major Depressive Disorder:&#xD;
&#xD;
          -  Male and female subjects between 18 and 65 years of age.&#xD;
&#xD;
          -  Subjects have been found eligible for other ETPB research protocols according to&#xD;
             01-M-0254.&#xD;
&#xD;
          -  Subjects must fulfill DSM-IV criteria for Major Depression based on clinical&#xD;
             assessment and confirmed by a structured diagnostic interview (SCID-P).&#xD;
&#xD;
          -  Subjects must be able to give written informed consent prior to participation in this&#xD;
             study.&#xD;
&#xD;
          -  For cognitive experiments utilizing language stimuli, only native English speakers&#xD;
             will be enrolled.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        Healthy Control:&#xD;
&#xD;
          -  Subjects with major medical or neurological disorders expected to influence cerebral&#xD;
             blood flow or morphology, or taking any medication that is likely to influence the&#xD;
             imaging parameters-of-interest within 3 weeks of scanning.&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding. Subjects will undergo pregnancy testing no&#xD;
             more than 24 hours prior to scanning.&#xD;
&#xD;
          -  Subjects with contraindication to MRI scanning such as aneurysm clips, implanted&#xD;
             neural stimulator, implanted cardiac pacemaker or auto-defibrillator, cochlear&#xD;
             implant, or ocular foreign body.&#xD;
&#xD;
          -  A history of drug or alcohol abuse within 1 year or a lifetime history of drug or&#xD;
             alcohol dependence (DSM-IV) or alcohol use disorder (DSM-V equivalent).&#xD;
&#xD;
          -  A current NIMH employee/staff or their immediate family member.&#xD;
&#xD;
        Major Depressive Disorder:&#xD;
&#xD;
          -  Presence of Axis 1 psychiatric diagnosis other than Major Depression or an Axis 2&#xD;
             disorder&#xD;
&#xD;
          -  Subjects with major medical or neurological disorders expected to influence cognitive&#xD;
             function or are taking any drugs likely to affect mood or cognitive function within 2&#xD;
             weeks of study participation. Depressed subjects will not be tapered/withdrawn from&#xD;
             medications under this study.&#xD;
&#xD;
          -  A history of drug or alcohol abuse within 1 year or a lifetime history of drug or&#xD;
             alcohol dependence (DSM-IV) or alcohol use disorder (DSM-V equivalent).&#xD;
&#xD;
          -  A current NIMH employee/staff or their immediate family member&#xD;
&#xD;
          -  Subjects with major medical or neurological disorders expected to influence cerebral&#xD;
             blood flow or morphology.&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding. Subjects will undergo pregnancy testing no&#xD;
             more than 24 hours prior to scanning.&#xD;
&#xD;
          -  Subjects with contraindication to MRI scanning such as aneurysm clips, implanted&#xD;
             neural stimulator, implanted cardiac pacemaker or auto-defibrillator, cochlear&#xD;
             implant, or ocular foreign body.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allison Nugent, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Mental Health (NIMH)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Allison Nugent, Ph.D.</last_name>
    <phone>(301) 451-8863</phone>
    <email>moodresearch@mail.nih.gov</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)</last_name>
      <phone>800-411-1222</phone>
      <phone_ext>TTY8664111010</phone_ext>
      <email>prpl@cc.nih.gov</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_2007-M-0021.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Drevets WC, Price JL, Simpson JR Jr, Todd RD, Reich T, Vannier M, Raichle ME. Subgenual prefrontal cortex abnormalities in mood disorders. Nature. 1997 Apr 24;386(6627):824-7.</citation>
    <PMID>9126739</PMID>
  </reference>
  <reference>
    <citation>Drevets WC, Ong√ºr D, Price JL. Neuroimaging abnormalities in the subgenual prefrontal cortex: implications for the pathophysiology of familial mood disorders. Mol Psychiatry. 1998 May;3(3):220-6, 190-1. Review.</citation>
    <PMID>9672897</PMID>
  </reference>
  <reference>
    <citation>Drevets WC. Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders. Curr Opin Neurobiol. 2001 Apr;11(2):240-9. Review.</citation>
    <PMID>11301246</PMID>
  </reference>
  <verification_date>October 8, 2021</verification_date>
  <study_first_submitted>November 7, 2006</study_first_submitted>
  <study_first_submitted_qc>November 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2006</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Morphometry</keyword>
  <keyword>BOLD</keyword>
  <keyword>fMRI</keyword>
  <keyword>Spectrometry</keyword>
  <keyword>Relaxometry</keyword>
  <keyword>Healthy Volunteer</keyword>
  <keyword>HV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Mood Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

